If a drug does a good job of treating lung cancer, but is less effective at combating pancreatic cancer, you might think that the price should be lower for pancreatic cancer patients. But it doesn’t work that way in the convoluted world of pharmaceutical pricing, where a one-size-fits-all approach is generally used.
Now, though, a new drug pricing scheme is gaining traction that would base payments on how well a medicine actually works.
Read Full Article »